Methoxsalen (Synonyms: 8-Methoxypsoralen; Xanthotoxin; 8-MOP)

Name: Methoxsalen
Brand: MedChemExpress
SKU: HY-30151
Rating: 5.0 (17 reviews)

Cat. No.: HY-30151 Purity: 99.97%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Methoxsalen (8-Methoxypsoralen) is a furanocoumarin compound used in psoralen, used in studies of psoriasis, eczema, vitiligo and some sun-exposed cutaneous lymphomas, and is a P450 inhibitor.

For research use only. We do not sell to patients.

CAS No. : 298-81-7

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	In-stock	Estimated Time of Arrival: December 31
25 g	In-stock	Estimated Time of Arrival: December 31
50 g	In-stock	Estimated Time of Arrival: December 31
> 100 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 17 publication(s) in Google Scholar

Other Forms of Methoxsalen:

17 Publications Citing Use of MCE Methoxsalen

Microbiological Assay

Bio/Physico-chemical Assay

: Methoxsalen purchased from MedChemExpress. Usage Cited in: Insect Biochem Mol Biol. 2022 Jul:146:103796. [Abstract]; Qualitative enzyme activities to Methoxsalen (xanthotoxin) with six recombinant mutants.

: Methoxsalen purchased from MedChemExpress. Usage Cited in: Clin Chem. 2019 Dec;65(12):1522-1531. [Abstract]; Top-ranked ingredients associated with false positives on the amphetamines and buprenorphine screens.

: Methoxsalen purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Nov 16;9(1):4820. [Abstract]; Compared with the SCD strain, LC50 values were significantly decreased to Methoxsalen (xanthotoxin, 4.1-fold) and 2-tridecanone (1.4-fold) in the knockout SCD-d6AE strain.

: Methoxsalen purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Nov 16;9(1):4820. [Abstract]; Metabolism of Methoxsalen (xanthotoxin), 2-tridecanone, and indoxacarb by recombinant P450s. CYP6AE subfamily enzymes were from H. armigera and CYP6B1 from Papilio polyxenes. Error bars represent mean values ± SEM (n = 4). Asterisk indicates that no significant metabolism was detected (limits of detection were 0.081, 0.033, and 0.016 pmol/min/pmol P450 for Methoxsalen (xanthotoxin), 2-tridecanone, and indoxacarb, respectively).

: Methoxsalen purchased from MedChemExpress. Usage Cited in: Nat Commun. 2018 Nov 16;9(1):4820. [Abstract]; The results showed that the CYP6AE19 and CYP6AE20 transcripts (>1000-fold induction in midgut and >100-fold induction in fat body) are very strongly induced by Methoxsalen (xanthotoxin). Furthermore, CYP6AE14 transcripts are induced in midgut (40-fold) after dietary exposure to gossypol.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Cytochrome P450 Isoform Specific Products:

View All Isoforms

CYP1 CYP2 CYP3 CYP4 CYP11 CYP17 Aromatase/CYP19A1 CYP26 CYP51 CYP1A2 CYP2D6 CYP2C9 CYP2C19 CYP3A CYP3A4 CYP17A1

Biological Activity
Purity & Documentation
References
Customer Review

Description

Methoxsalen (8-Methoxypsoralen) is a furanocoumarin compound used in psoralen, used in studies of psoriasis, eczema, vitiligo and some sun-exposed cutaneous lymphomas, and is a P450 inhibitor.

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	>30 μM Compound: 8-MOP	Antiproliferative activity against human A431 cells after 24 hrs by trypan blue dye assay Antiproliferative activity against human A431 cells after 24 hrs by trypan blue dye assay	[PMID: 22537681]
A-431	IC₅₀	2.48 μM Compound: 8-MOP	Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound	[PMID: 8893844]
A-431	IC₅₀	25 μM Compound: 8-MOP	Antiproliferative activity against human A431 cells incubated for 1 hr with inhibitor followed by UV irradiation measured after 24 hrs by trypan blue dye assay Antiproliferative activity against human A431 cells incubated for 1 hr with inhibitor followed by UV irradiation measured after 24 hrs by trypan blue dye assay	[PMID: 22537681]
AGS	IC₅₀	>100 μM Compound: Xanthotoxin	Anti-proliferative activity against human AGS cells after 48 hrs by MTT assay Anti-proliferative activity against human AGS cells after 48 hrs by MTT assay	[PMID: 28947149]
HCT-116	IC₅₀	>100 μM Compound: 6	Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay Cytotoxicity against human HCT116 cells after 96 hrs by MTT assay	[PMID: 23746477]
HeLa	IC₅₀	>20 μM Compound: 8 -MOP	Antiproliferative activity against HeLa (human cervix adenocarcinoma cells) in dark condition Antiproliferative activity against HeLa (human cervix adenocarcinoma cells) in dark condition	[PMID: 12930143]
HeLa	IC₅₀	>20 μM Compound: 8-MOP	The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the dark The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the dark	[PMID: 10543884]
HeLa	IC₅₀	>20 μM Compound: 8-MOP	Antiproliferative activity against HeLa cells in dark Antiproliferative activity against HeLa cells in dark	[PMID: 16821791]
HeLa	IC₅₀	>20 μM Compound: 8-MOP	Photo-antiproliferative activity against human HeLa cells under dark condition Photo-antiproliferative activity against human HeLa cells under dark condition	[PMID: 19359172]
HeLa	IC₅₀	>30 μM Compound: 8-MOP	Antiproliferative activity against human HeLa cells after 24 hrs by trypan blue dye assay Antiproliferative activity against human HeLa cells after 24 hrs by trypan blue dye assay	[PMID: 22537681]
HeLa	IC₅₀	10 μM Compound: 8-MOP	Antiproliferative activity against human HeLa cells incubated for 1 hr with inhibitor followed by UV irradiation measured after 24 hrs by trypan blue dye assay Antiproliferative activity against human HeLa cells incubated for 1 hr with inhibitor followed by UV irradiation measured after 24 hrs by trypan blue dye assay	[PMID: 22537681]
HeLa	IC₅₀	10 mM Compound: 8-MOP (8-Methoxypsoralen)	In vitro antiproliferative activity against human cervix adenocarcinoma (HeLa) cells In vitro antiproliferative activity against human cervix adenocarcinoma (HeLa) cells	[PMID: 10673096]
HeLa	IC₅₀	10 μM Compound: 8 -MOP	Antiproliferative activity against HeLa (human cervix adenocarcinoma cells) after exposure to UV light Antiproliferative activity against HeLa (human cervix adenocarcinoma cells) after exposure to UV light	[PMID: 12930143]
HeLa	IC₅₀	10 μM Compound: 8-MOP	The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the presence of UVA(ultra violet A irradiated) The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the presence of UVA(ultra violet A irradiated)	[PMID: 10543884]
HeLa	IC₅₀	10 μM Compound: 8-MOP	Compound was evaluated for its antiproliferative activity after UVA irradiation on human tumor HeLa cell line Compound was evaluated for its antiproliferative activity after UVA irradiation on human tumor HeLa cell line	[PMID: 11965365]
HeLa	IC₅₀	10 μM Compound: 8-MOP	Antiproliferative activity against HeLa cells in presence of 0.789 J/cm2 UVA light Antiproliferative activity against HeLa cells in presence of 0.789 J/cm2 UVA light	[PMID: 16821791]
HeLa	IC₅₀	10 μM Compound: 8-MOP	Photo-antiproliferative activity against human HeLa cells exposed to 365 nm, 0.793 Jcm'-2 UVA light Photo-antiproliferative activity against human HeLa cells exposed to 365 nm, 0.793 Jcm'-2 UVA light	[PMID: 19359172]
HeLa	IC₅₀	3.16 μM Compound: 8-MOP	Compound was evaluated for cell growth inhibition against HeLa cell line by irradiation in the presence of examined compound Compound was evaluated for cell growth inhibition against HeLa cell line by irradiation in the presence of examined compound	[PMID: 8893844]
HeLa	IC₅₀	7.6 μg/mL Compound: Xanthotoxin	Antitumor activity against human HeLa cells after 72 hrs by MTS assay Antitumor activity against human HeLa cells after 72 hrs by MTS assay	[PMID: 19217697]
HL-60	IC₅₀	>20 μM Compound: 8-MOP	Cytotoxicity against human HL60 cells treated under dark condition after 24 hrs by trypan blue assay Cytotoxicity against human HL60 cells treated under dark condition after 24 hrs by trypan blue assay	[PMID: 20615713]
HL-60	IC₅₀	>20 μM Compound: 8-MOP	Cytotoxicity against human HL60 cells treated under dark condition after 72 hrs by trypan blue assay Cytotoxicity against human HL60 cells treated under dark condition after 72 hrs by trypan blue assay	[PMID: 20615713]
HL-60	IC₅₀	>20 μM Compound: 8 -MOP	Antiproliferative activity against HL-60 (human promyelocytic leukemic cells) in dark condition Antiproliferative activity against HL-60 (human promyelocytic leukemic cells) in dark condition	[PMID: 12930143]
HL-60	IC₅₀	>20 μM Compound: 8-MOP	The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the dark The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the dark	[PMID: 10543884]
HL-60	IC₅₀	>20 μM Compound: 8-MOP	Antiproliferative activity against HL60 cells in dark Antiproliferative activity against HL60 cells in dark	[PMID: 16821791]
HL-60	IC₅₀	0.75 μM Compound: 8-MOP	Compound was evaluated for cell growth inhibition against HL 60 cell line by irradiation in the presence of examined compound Compound was evaluated for cell growth inhibition against HL 60 cell line by irradiation in the presence of examined compound	[PMID: 8893844]
HL-60	IC₅₀	1.2 μM Compound: 8-MOP	Photocytotoxicity against human HL-60 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human HL-60 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
HL-60	IC₅₀	1.2 μM Compound: 8-MOP	Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 3.2 joule/cm2 UVA dose Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 3.2 joule/cm2 UVA dose	[PMID: 15837311]
HL-60	IC₅₀	1.4 μM Compound: 8-MOP	Photocytotoxicity against human HL-60 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human HL-60 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
HL-60	IC₅₀	1.4 μM Compound: 8-MOP	Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 2.5 joule/cm2 UVA dose Cytotoxicity against HL-60 (human fibrosarcoma) cell line at 2.5 joule/cm2 UVA dose	[PMID: 15837311]
HL-60	IC₅₀	5.4 μM Compound: 8-MOP	Cytotoxicity against human HL60 cells after 24 hrs by trypan blue assay in presence of 0.789 J cm-2 of UVA light Cytotoxicity against human HL60 cells after 24 hrs by trypan blue assay in presence of 0.789 J cm-2 of UVA light	[PMID: 20615713]
HL-60	IC₅₀	5.4 mM Compound: 8-MOP (8-Methoxypsoralen)	In vitro antiproliferative activity against human promyelocytic (HL-60) cells In vitro antiproliferative activity against human promyelocytic (HL-60) cells	[PMID: 10673096]
HL-60	IC₅₀	5.4 μM Compound: 8 -MOP	Antiproliferative activity against HL-60 (human promyelocytic leukemic cells) after exposure to UV light Antiproliferative activity against HL-60 (human promyelocytic leukemic cells) after exposure to UV light	[PMID: 12930143]
HL-60	IC₅₀	5.4 μM Compound: 8-MOP	The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the presence of UVA(ultra violet A irradiated) The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the presence of UVA(ultra violet A irradiated)	[PMID: 10543884]
HL-60	IC₅₀	5.4 μM Compound: 8-MOP	Compound was evaluated for its antiproliferative activity after UVA irradiation on human tumor HL-60 cell line Compound was evaluated for its antiproliferative activity after UVA irradiation on human tumor HL-60 cell line	[PMID: 11965365]
HL-60	IC₅₀	5.4 μM Compound: 8-MOP	Antiproliferative activity against HL60 cells in presence of 0.789 J/cm2 UVA light Antiproliferative activity against HL60 cells in presence of 0.789 J/cm2 UVA light	[PMID: 16821791]
HT-1080	IC₅₀	1.5 μM Compound: 8-MOP	Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line	[PMID: 12873520]
HT-1080	IC₅₀	1.9 μM Compound: 8-MOP	Photocytotoxicity against human HT1080 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human HT1080 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
HT-1080	IC₅₀	2.1 μM Compound: 8-MOP	Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line	[PMID: 12873520]
HT-1080	IC₅₀	7.8 μM Compound: 8-MOP	Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line	[PMID: 12873520]
HT-1080	IC₅₀	7.8 μM Compound: 8-MOP	Photocytotoxicity against human HT1080 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human HT1080 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
HT-29	IC₅₀	>100 μM Compound: 6	Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay Cytotoxicity against human HT-29 cells after 96 hrs by MTT assay	[PMID: 23746477]
Jurkat	IC₅₀	>20 μM Compound: 8MOP	Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay Cytotoxicity against human Jurkat cells after 72 hrs by MTT assay	[PMID: 19230658]
Jurkat	IC₅₀	1.2 μM Compound: 8MOP	Phototoxicity against human Jurkat cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay Phototoxicity against human Jurkat cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay	[PMID: 19230658]
Jurkat	IC₅₀	1.2 μM Compound: 8-MOP	Photocytotoxicity against human JURKAT cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human JURKAT cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
K562	IC₅₀	>20 μM Compound: 8MOP	Cytotoxicity against human K562 cells after 72 hrs by MTT assay Cytotoxicity against human K562 cells after 72 hrs by MTT assay	[PMID: 19230658]
L02	IC₅₀	>100 μM Compound: Xanthotoxin	Anti-proliferative activity against human L02 cells after 48 hrs by MTT assay Anti-proliferative activity against human L02 cells after 48 hrs by MTT assay	[PMID: 28947149]
LoVo	IC₅₀	>20 μM Compound: 8MOP	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 19230658]
LoVo	IC₅₀	0.4 μM Compound: 8-MOP	Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 6.5 joule/cm2 UVA dose Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 6.5 joule/cm2 UVA dose	[PMID: 15837311]
LoVo	IC₅₀	0.7 μM Compound: 8MOP	Phototoxicity against human LoVo cells exposed to irradiation with 3.75 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay Phototoxicity against human LoVo cells exposed to irradiation with 3.75 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay	[PMID: 19230658]
LoVo	IC₅₀	0.7 μM Compound: 8-MOP	Photocytotoxicity against human LoVo cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human LoVo cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
LoVo	IC₅₀	0.7 μM Compound: 8-MOP	Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 3.2 joule/cm2 UVA dose Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 3.2 joule/cm2 UVA dose	[PMID: 15837311]
LoVo	IC₅₀	1.1 μM Compound: 8MOP	Phototoxicity against human LoVo cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay Phototoxicity against human LoVo cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay	[PMID: 19230658]
LoVo	IC₅₀	1.1 μM Compound: 8-MOP	Photocytotoxicity against human LoVo cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human LoVo cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
LoVo	IC₅₀	1.1 μM Compound: 8-MOP	Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 2.5 joule/cm2 UVA dose Cytotoxicity against LoVo (human intestinal adenocarcinoma) cell line at 2.5 joule/cm2 UVA dose	[PMID: 15837311]
MES-SA/Dx5	IC₅₀	3.1 μM Compound: 6	Cytotoxicity against human MES-SA/Dx5 cells after 96 hrs by MTT assay Cytotoxicity against human MES-SA/Dx5 cells after 96 hrs by MTT assay	[PMID: 23746477]
NCTC-2544	IC₅₀	>20 μM Compound: 8MOP	Cytotoxicity against human NCTC-2544 cells after 72 hrs by MTT assay Cytotoxicity against human NCTC-2544 cells after 72 hrs by MTT assay	[PMID: 19230658]
NCTC-2544	IC₅₀	0.9 μM Compound: 8-MOP	Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 3.75 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
NCTC-2544	IC₅₀	5.5 μM Compound: 8MOP	Phototoxicity against human NCTC-2544 cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay Phototoxicity against human NCTC-2544 cells exposed to irradiation with 2.5 J/cm'2 UVA light prior to 72 hrs drug exposure by MTT assay	[PMID: 19230658]
NCTC-2544	IC₅₀	5.5 μM Compound: 8-MOP	Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay Photocytotoxicity against human NCTC 2544 cells treated 30 mins before 2.5 J/cm'2 UVA irradiation measured after 72 hrs by MTT assay	[PMID: 18951030]
PAM212	IC₅₀	>100 μM Compound: 2; 8-MOP	Dark toxicity against mouse PAM212 cells assessed as cell growth inhibition incubated for 30 mins under dark condition measured after 5 days by coulter counting method Dark toxicity against mouse PAM212 cells assessed as cell growth inhibition incubated for 30 mins under dark condition measured after 5 days by coulter counting method	[PMID: 30638875]
PAM212	IC₅₀	>100 μM Compound: 2; 8-MOP	Dark toxicity against mouse PAM212 cells assessed as cell growth inhibition incubated for 5 days under dark condition by coulter counting method Dark toxicity against mouse PAM212 cells assessed as cell growth inhibition incubated for 5 days under dark condition by coulter counting method	[PMID: 30638875]
PAM212	IC₅₀	0.1 μM Compound: 2; 8-MOP	Phototoxicity against mouse PAM212 cells assessed as cell growth inhibition preincubated for 30 mins followed by 1.28 J/cm2 UV light exposure and measured after 5 days by coulter counting method Phototoxicity against mouse PAM212 cells assessed as cell growth inhibition preincubated for 30 mins followed by 1.28 J/cm2 UV light exposure and measured after 5 days by coulter counting method	[PMID: 30638875]
PANC-1	IC₅₀	83.3 μM Compound: 6	Cytotoxicity against human PANC1 cells after 96 hrs by MTT assay Cytotoxicity against human PANC1 cells after 96 hrs by MTT assay	[PMID: 23746477]
Panel leukemia (Carcinoma cell lines)	IC₅₀	>100 μM Compound: 1	In vitro photocytotoxicity is evaluated against human chronic myeloid leukemia cells grown in culture under the dark conditions In vitro photocytotoxicity is evaluated against human chronic myeloid leukemia cells grown in culture under the dark conditions	[PMID: 8164263]
Panel leukemia (Carcinoma cell lines)	IC₅₀	100 μM Compound: 1	In vitro photocytotoxicity is evaluated against human chronic myeloid leukemia cells grown in culture irradiated at 366 nM In vitro photocytotoxicity is evaluated against human chronic myeloid leukemia cells grown in culture irradiated at 366 nM	[PMID: 8164263]
Raji	IC₅₀	490 molar ratio Compound: 7	Inhibition of TPA-induced EBV-early antigen activation in human Raji cells Inhibition of TPA-induced EBV-early antigen activation in human Raji cells	[PMID: 16441065]

In Vivo

Methoxsalen (15mg/kg, i.p, single dose) increases nicotine’s C_max prolongs the plasma nicotine half-life (fourfold increase), decreases its clearance (sixfold decrease), and increases its AUC^[1].
Methoxsalen (15mg/kg, i.p, single dose) enhances the potency of pharmacological effects of oral nicotine (i.e., body temperature and analgesia)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male adult ICR mice^[1]
Dosage:	15 mg/kg
Administration:	Intraperitoneal injection (i.p.), single dose
Result:	Increased nicotine plasma levels were still above 10ng/ml at 6hr. Induced nicotine’s antinociceptive and hypothermic lasted close to 6 and 24 hr.

Clinical Trial

Molecular Weight

216.19

Formula

C₁₂H₈O₄

CAS No.

298-81-7

Appearance

Solid

Color

White to light yellow

SMILES

O=C1OC(C(C=C1)=C2)=C(OC)C3=C2C=CO3

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (231.28 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	4.6256 mL	23.1278 mL	46.2556 mL
5 mM	0.9251 mL	4.6256 mL	9.2511 mL
10 mM	0.4626 mL	2.3128 mL	4.6256 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (11.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (11.56 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.98%

Select Batch:

Data Sheet (277 KB) SDS (557 KB)

COA (252 KB) HNMR (115 KB) RP-HPLC (147 KB)

Handling Instructions (2659 KB)

References

[1]. Alsharari SD, et al. Pharmacokinetic and Pharmacodynamics Studies of Nicotine After Oral Administration in Mice: Effects of Methoxsalen, a CYP2A5/6 Inhibitor. Nicotine Tob Res. 2014 Jan;16(1):18-25. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	4.6256 mL	23.1278 mL	46.2556 mL	115.6390 mL
	5 mM	0.9251 mL	4.6256 mL	9.2511 mL	23.1278 mL
	10 mM	0.4626 mL	2.3128 mL	4.6256 mL	11.5639 mL
	15 mM	0.3084 mL	1.5419 mL	3.0837 mL	7.7093 mL
	20 mM	0.2313 mL	1.1564 mL	2.3128 mL	5.7820 mL
	25 mM	0.1850 mL	0.9251 mL	1.8502 mL	4.6256 mL
	30 mM	0.1542 mL	0.7709 mL	1.5419 mL	3.8546 mL
	40 mM	0.1156 mL	0.5782 mL	1.1564 mL	2.8910 mL
	50 mM	0.0925 mL	0.4626 mL	0.9251 mL	2.3128 mL
	60 mM	0.0771 mL	0.3855 mL	0.7709 mL	1.9273 mL
	80 mM	0.0578 mL	0.2891 mL	0.5782 mL	1.4455 mL
	100 mM	0.0463 mL	0.2313 mL	0.4626 mL	1.1564 mL

Methoxsalen Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Methoxsalen298-81-78-Methoxypsoralen Xanthotoxin 8-MOPCytochrome P450CYPsInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Methoxsalen (Synonyms: 8-Methoxypsoralen; Xanthotoxin; 8-MOP)

Customer Review

Other Forms of Methoxsalen:

Methoxsalen Related Antibodies

17 Publications Citing Use of MCE Methoxsalen

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Cytochrome P450 Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Methoxsalen Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report